Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Inivata invokes $25m from NeoGenomics
CRUK and Cambridge precision cancer diagnostics spinout Inivata has secured $25m from NeoGenomics as part of a deal that includes an acquisition option.
Truework verifies $30m
Truework, which provides software to run employment and income background checks, secured the return of Sequoia Capital and Khosla Ventures to bring its total to $45m.
Octant circles $30m series A
Led by UCLA’s Sri Kosuri, Octant is working on drugs for complex diseases and will use the series A funding to further develop its platform.
Commsat sets up $38m series B
AVIC invested in the CAS-backed industrial internet-of-things satellite operator Commsat's latest round to bring its overall funding to $68.2m.
Immunai surfaces with $20m seed round
Immune cell mapping technology developer Immunai has emerged from stealth to commercialise inventions from Stanford and PICI labs.
Modulus unearths $25.2m
University of Tokyo and Keio University joined multiple corporates in a round that brought the pre-clinical drug developer's funding haul to $33.1m.
Featurespace impresses for $36.8m round
Cambridge's Featurespace boosted its funding total to $108m having assembled a consortium including existing investor IP Group for its latest round.
Taysha stakes out $30m seed round
UT Southwestern has formed central nervous system diseases treatment developer Taysha Gene Therapies with executives who previously worked for OSU's Avexis.

Other News

Actym Therapeutics actions $34m
Boehringer Ingelheim Venture Fund co-led a series A round set to drive clinical work on UC Berkeley-founded Actym Therapeutics' immunotherapy pipeline.
LifeSprout bolts on series A funding
JHU-founded restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.
Aptbio measures out $28.3m
CAS Shanghai Institutes for Biological Sciences spinout Aptbio secured funding to enhance its mass spectrometry drug screening business.
Nitrome hits the gas with $38m series A
The Parkinson's disease therapy developer completed a series A round featuring QB3-aligned Mission Bay Capital.
New Horizon brings $20m series D
Dumac contributed to a round that took the total raised by the cancer screening system developer past the $130m mark.
Lunaphore relights series C round
EPFL spinout Lunaphore has received $2m in a series C extension provided by Swiss Entrepreneurs Fund, adding to an initial $23.6m tranche led by PHC Holdings three months ago.

Editor's Picks

Tel Aviv partners with Tata
Tel Aviv University announces $20m commercialisation fund with Tata Industries.
UK graphene research nets $35m backing
Cell Medica raises $26.5m
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.
Revolymer sticks to AIM in IPO
Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.
test reg